Login to Your Account



Other News To Note


Wednesday, October 30, 2013
• Pharmalink AB, of Stockholm, said Busulipo, a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation, received orphan drug designation from the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription